Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:08 PM ET 10-Q
Financial Results Grayscale Litecoin Trust (LTC) LTCN

Grayscale Litecoin Trust Q1 2026 Results: Net Income $47.3M, Up 22.8% YoY

Grayscale Litecoin Trust reported a significant increase in net assets from operations of $47.3 million for the quarter ended September 30, 2026, driven primarily by $48.5 million in unrealized appreciation of LTC. The Trust's Principal Market NAV per Share rose from $3.39 to $5.35 during the period, while the total number of outstanding shares remained constant at 24,252,100.

Key figure
Net income $47.3M · +22.8% YoY
4:08 PM ET 8-K
Financial Results Electromed, Inc. ELMD

Electromed Financial Results

Electromed reported its 16th consecutive quarter of year-over-year revenue and operating income growth for the fiscal first quarter ended September 30, 2026. Net revenues increased 10.6% to $18.7 million, driven by strong performance in the core homecare market, while net income rose 29.3% to $2.8 million. The company remains debt-free and returned $4.3 million to shareholders through share repurchases during the quarter.

Term
Q1 2027

“We delivered our 16th consecutive quarter of year-over-year revenue and operating income growth, with double-digit revenue growth, a 30.7% increase in operating income and an 80.0% gross margin—demonstrating the strength of our direct-to-patient model and operating leverage. We also returned $4.3 million to shareholders through share repurchases while remaining debt-free. With a strong balance sheet and high-performing sales and fulfillment teams, Electromed is well positioned to bring SmartVest® therapy to more patients who need to breathe easier.”

Jim Cunniff, President and Chief Executive Officer
4:08 PM ET 8-K
Financial Results Gladstone Land Corp LAND

Gladstone Land Financial Results

Gladstone Land reported its Q3 2026 financial results, highlighting a significant increase in participation rent revenue to $16.8 million compared to $5.4 million in the prior-year quarter. The results were driven by strong pricing for almonds and pistachios, including a 67% increase in the initial base price for the 2026 pistachio crop.

Term
Q3 2026
4:08 PM ET 8-K
Financial Results Silicon Laboratories Inc. SLAB

Silicon Laboratories Financial Results

Silicon Laboratories reported Q3 2026 revenue of $251 million, a 22% year-over-year increase driven by record medical revenue and broad-based growth in Industrial & Commercial and Home & Life segments. GAAP diluted EPS improved to $0.26 from a loss in the prior year, while non-GAAP EPS rose 228% to $1.05. The company suspended forward-looking guidance due to its pending acquisition by Texas Instruments.

Term
Q3 2026

“We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued. Earnings significantly outpaced revenue growth, a result of strong operational execution by the team. Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.”

Matt Johnson, President and Chief Executive Officer
4:08 PM ET 10-Q
Financial Results Rigetti Computing, Inc. RGTI ▶ Call

Rigetti Computing Q3 2026 Results: Net Loss of $3.14M, Loss Narrows

Rigetti Computing reported total assets of $623.9 million as of September 30, 2026, a decrease from $666.6 million at year-end 2025. The company maintains a strong liquidity position with $45.8 million in cash and $337.5 million in short-term investments, while common stock outstanding reached 342,783,018 shares as of November 6, 2026.

Key figure
Net loss $3.14M
4:08 PM ET Form 4
Insider Selling Intapp, Inc. INTA

Intapp CEO John T. Hall Sells $132K of Stock

John T. Hall, CEO, sold 3,000 shares of Intapp, Inc. at $43.75 to $44.32 a share (average $44.12) in 2 transactions, worth $132K in total on Nov 9, 2026. Shares held after the trade: 5,814,808 (-0.0%).

Value
$132K
Shares
3,000
Average price
$44.12
Role
CEO
Holding change
-0.0%
Trade date
Nov 9, 2026
4:08 PM ET 8-K
Capital Raise Pacific Biosciences of California, Inc. PACB

Pacific Biosciences of California Capital Raise

Pacific Biosciences of California entered into a sales agreement with Allen & Company LLC to establish an at-the-market (ATM) equity offering program. The company may sell up to $100 million of its common stock from time to time at its discretion. Allen & Company will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds.

Counterparty
Allen & Company LLC
4:08 PM ET 10-Q
Financial Results Orion180 Insurance Group Inc. OIG

Orion180 Insurance Group Q3 2026 Results: Net Income $11.5M, Up 32.3% YoY

Orion180 Insurance Group Inc. reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $134.0 million from $84.5 million in the prior year. The company successfully completed its initial public offering during the third quarter, raising $224.4 million in net proceeds, which contributed to a substantial increase in total assets to $936.9 million.

Key figure
Net income $11.5M · +32.3% YoY
4:08 PM ET 10-Q
Financial Results Grocery Outlet Holding Corp. GO

Grocery Outlet Holding Q3 2026 Results: Net Income $13.3M, Up 14.5% YoY

Grocery Outlet reported a net loss of $161.4 million for the 39 weeks ended October 3, 2026, primarily driven by a $158.0 million goodwill impairment charge and $20.1 million in restructuring charges. Despite these non-cash and one-time costs, net sales for the period grew slightly to $3.54 billion compared to $3.47 billion in the prior year period.

Key figure
Net income $13.3M · +14.5% YoY
4:08 PM ET 8-K
Financial Results Gevo, Inc. GEVO

Gevo Financial Results

Gevo reported record third quarter 2026 financial results, driven by its carbon business and the sale of Canadian Clean Fuel Regulation (CFR) credits. The company achieved net income of $23 million and record revenue of $83 million, significantly improving its cash position to $68 million.

Term
Q3 2026

“The quarter marked our strongest financial performance to date, with record revenue, net income, Adjusted EBITDA and cash flow from operations. We said we would build a carbon business that stands on its own in 2026. These results show it’s working.”

Paul Bloom, Chief Executive Officer

“Gevo has a powerful growth platform built on low-carbon fuels, carbon and maximizing incentives. We have focused development around our existing operations, improving margins and near-term cash flow, with a portfolio of growth projects we believe will create substantial shareholder value.”

Paul Bloom, Chief Executive Officer
4:08 PM ET 10-Q
Financial Results Anterix Inc. ATEX

Anterix Q2 2026 Results: Net Loss of $4.99M

Anterix Inc. reported spectrum revenue of $3.9 million for the six months ended September 30, 2026, up from $3.0 million in the prior year. The company maintained a strong liquidity position with $107.5 million in cash and cash equivalents, while continuing to execute its strategy of commercializing 900 MHz spectrum assets for utility and critical infrastructure customers.

Key figure
Net loss $4.99M
4:08 PM ET Form 4
Insider Selling Incyte Corp INCY

Incyte CMO & Head of Late-Stage Dev. Steven H. Stein Sells $28.4M of Stock

Steven H. Stein, CMO & Head of Late-Stage Dev., sold 240,193 shares of Incyte Corp at $116.06 to $119.66 a share (average $118.39) in 5 transactions, worth $28.4M in total on Nov 6, 2026. Shares held after the trade: 30,916 (-61.1%).

Value
$28.4M
Shares
240,193
Average price
$118.39
Role
CMO & Head of Late-Stage Dev.
Holding change
-61.1%
Trade date
Nov 6, 2026
4:08 PM ET 8-K
Regulatory Approval Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Regulatory Approval

Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
4:08 PM ET 10-Q
Financial Results Janus International Group, Inc. JBI

Janus International Group Q3 2026 Results: Net Loss of $13.3M

Janus International Group reported a net loss of $13.3 million for the third quarter of 2026, compared to a net income of $15.2 million in the prior year period, primarily driven by an $18.3 million impairment charge and higher cost of revenues. Total revenues for the quarter decreased slightly to $213.1 million from $219.3 million, while the company continued its share repurchase program, increasing treasury stock to $145.6 million.

Key figure
Net loss $13.3M
4:08 PM ET 8-K
Financial Results Qt Imaging Holdings, Inc. QTI

Qt Imaging Holdings Financial Results

QT Imaging reported Q3 2026 revenue of $7.3 million, a 75% year-over-year increase, driven by the sale of 15 Breast Acoustic CT scanners. The company achieved a major regulatory milestone with CMS establishing a Medicare hospital outpatient payment pathway for diagnostic QTscan examinations effective January 1, 2027. Full-year 2026 revenue guidance was adjusted to approximately $34 million due to international shipment delays caused by conflict in the Middle East.

Term
Q3 2026

“Our third-quarter results demonstrate the continued growth of QT Imaging, with revenue increasing 75% year over year and reaching $21.3 million for the first nine months of 2026, approximately double the prior-year period.”

Dr. Raluca Dinu, Chief Executive Officer of QT Imaging

“A major milestone is the recent CMS decision establishing separate Medicare hospital outpatient payment for medically necessary diagnostic QTscan examinations, effective January 1, 2027. Together with our dedicated billing code, effective October 1, this decision removes a significant reimbursement uncertainty and strengthens our ability to expand into U.S. hospitals and health systems.”

Dr. Raluca Dinu, Chief Executive Officer of QT Imaging
4:08 PM ET 8-K
Dividend Phillips Edison & Company, Inc. PECO

Phillips Edison & Company Dividend

Phillips Edison & Company's Board of Directors declared monthly cash dividends of $0.115 per share for December 2026, January 2027, and February 2027. The distributions are payable to stockholders of record on December 15, January 15, and February 16, respectively. Operating partnership unit holders will receive distributions at the same rate.

4:08 PM ET 8-K
Investor Presentation Prime Medicine, Inc. PRME

Prime Medicine Investor Presentation

Prime Medicine filed an updated corporate presentation and provided preliminary financial estimates for the quarter ended September 30, 2026. The company estimated its cash, cash equivalents, and short-term investments at approximately $61.2 million, excluding restricted cash. The presentation outlines the company's strategic pipeline, including upcoming clinical data readouts for PM577a and PM647 expected in 2027.

4:08 PM ET 8-K
Financial Results Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals Financial Results

INOVIO reported Q3 2026 financial results and highlighted the landmark FDA accelerated approval of VOCERYQ, the first-ever approved DNA medicine, for the treatment of Recurrent Respiratory Papillomatosis (RRP). The company recently completed a public offering raising $80.5 million in net proceeds to support the commercial launch of VOCERYQ, which is expected to be available for order in early 2027.

“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients.”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer

“Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
4:08 PM ET Form 4
Insider Selling Visa Inc. V

Visa General Counsel Julie B. Rottenberg Sells $790K of Stock

Julie B. Rottenberg, General Counsel, sold 1,867 shares of Visa Inc. at $423.00 a share, worth $790K in total on Nov 9, 2026. Shares held after the trade: 18,404 (-9.2%).

Value
$790K
Shares
1,867
Price
$423.00
Role
General Counsel
Holding change
-9.2%
Trade date
Nov 9, 2026
4:08 PM ET 8-K
Executive Compensation Albertsons Companies, Inc. ACI

Albertsons Companies Executive Compensation

Albertsons Companies appointed Andrew Murray as Executive Vice President and Chief Financial Officer, effective January 17, 2027. Murray's compensation package includes a $900,000 base salary, a $1 million cash sign-on bonus, and a $1 million sign-on equity award, alongside a $3.5 million target annual equity award beginning in FY26. He succeeds Cody Perdue, who will return to his role as SVP of Treasury, Investor Relations and Risk.

Counterparty
Andrew Murray
4:08 PM ET Form 4
Insider Selling Mexican Economic Development Inc FMX

Mexican Economic Development Director of Corporate Control Attolini Gerardo Estrada Sells $180K of Stock

Attolini Gerardo Estrada, Director of Corporate Control, sold 13,936 shares of Mexican Economic Development Inc at $12.89 a share, worth $180K in total on Nov 6, 2026. Shares held after the trade: 425,227 (-3.2%).

Value
$180K
Shares
13,936
Price
$12.89
Role
Director of Corporate Control
Holding change
-3.2%
Trade date
Nov 6, 2026
4:08 PM ET 8-K
Financial Results Beachbody Company, Inc. BODI

Beachbody Company Financial Results

Beachbody (BODi) reported its fifth consecutive quarter of net income and operating income for Q3 2026, with net income and Adjusted EBITDA exceeding the high end of guidance. While total revenue declined to $45.2 million from $59.9 million year-over-year, the company maintained a 70.7% gross margin and achieved its twelfth consecutive quarter of positive Adjusted EBITDA.

Term
Q3 2026

“Net income and adjusted EBITDA exceeded the high end of our guidance and revenue met expectations as we continue to transform our business model. As the proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health, we are executing on our omni-channel strategy to place our iconic brands wherever shoppers are.”

Carl Daikeler, co-founder and BODi’s Chief Executive Officer

“Our third quarter results mark our twelfth consecutive quarter of positive Adjusted EBITDA and our fifth consecutive quarter of double-digit Adjusted EBITDA margins, reflecting the operating discipline we have built into this company.”

Mark Goldston, BODi’s Executive Chairman
4:08 PM ET 10-Q
Financial Results Braveheart Bio, Inc. BRVE

Braveheart Bio Q3 2026 Results: Net Loss of $26.5M, Loss Narrows

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead candidate BHB-1893 for hypertrophic cardiomyopathy (HCM). The company reports a limited operating history with significant losses and expects to require substantial additional funding to support its ongoing clinical trials, including LIONHEART-HCM and TRUEHEART-HCM.

Key figure
Net loss $26.5M
4:08 PM ET 8-K
Financial Results Airgain Inc AIRG

Airgain Financial Results

Airgain reported Q3 2026 revenue of $15.3 million, up 12% sequentially and 9% year-over-year, driven by strong momentum in its enterprise IoT business. The company achieved a non-GAAP net income of $0.5 million and secured new design wins for AI data center infrastructure, though it continues to navigate near-term supply constraints.

Term
Q3 2026

“Airgain delivered another strong quarter of progress, with revenue increasing 12% quarter-over-quarter and 9% year-over-year, driven by continued momentum in our enterprise IoT business.”

Jacob Suen, President and CEO of Airgain

“Our results reflect growing demand across established industrial applications, along with new opportunities in areas such as AI data center infrastructure.”

Jacob Suen, President and CEO of Airgain
4:08 PM ET 8-K
Financial Results Dermata Therapeutics, Inc. DRMA

Dermata Therapeutics Financial Results

Dermata Therapeutics reported financial results for the third quarter of 2026, highlighting its transition to a revenue-generating company following the August 2025 launch of Tome Foundational Treatment. The company reported its first product revenue and noted that approximately 30% of orders were generated via subscriptions.

Term
Q3 2026

“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business.”

Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer

“With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder.”

Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer
4:07 PM ET 8-K
Financial Results Mobile Infrastructure Corp BEEP

Mobile Infrastructure Financial Results

Mobile Infrastructure Corporation reported its third quarter 2026 financial results, highlighted by a 12.8% increase in same-location revenue and an 18.4% increase in same-location NOI. The company achieved record RevPAS growth of 16% driven by a 13 percentage point improvement in utilization across its parking portfolio.

Term
Q3 2026

“We are pleased with our third quarter results, marking Mobile’s strongest operating quarter of 2026, building strong momentum heading into 2027, and achieving our highest utilization and RevPAS to date.”

Stephanie Hogue, Chief Executive Officer

“At the start of the year, we discussed our strategy of building utilization first, establishing a larger and more durable base of recurring and transient demand, and following this with improved, sustainable pricing as utilization improves. Our results in the third quarter evidence strong execution as our strategy translates into earnings improvement.”

Stephanie Hogue, Chief Executive Officer
4:07 PM ET Form 4
Insider Selling Allstate Corp ALL

Allstate EVP, CLO and General Counsel Christine M. DeBiase Sells $7.5M of Stock

Christine M. DeBiase, EVP, CLO and General Counsel, sold 28,652 shares of Allstate Corp at $261.42 to $261.91 a share (average $261.78) in 2 transactions, worth $7.5M in total on Nov 6, 2026. Shares held after the trade: 12,067 (-37.6%).

Value
$7.5M
Shares
28,652
Average price
$261.78
Role
EVP, CLO and General Counsel
Holding change
-37.6%
Trade date
Nov 6, 2026
4:07 PM ET 8-K
Financial Results QumulusAI, Inc. QMLS

QumulusAI Financial Results

QumulusAI reported third quarter 2026 revenue of $14.8 million, a 376% increase year-over-year, driven by its neocloud compute infrastructure. The company achieved its first positive Adjusted EBITDA of $3.7 million while cumulative signed customer contract value surpassed $500 million following new agreements for NVIDIA Blackwell GPU clusters.

Term
Q3 2026

“Revenue doubled again this quarter, and remaining performance obligations grew to $515.0 million from $173.1 million at the end of the second quarter. That’s the model doing its job: we sell the capacity before we energize it, we deploy into pockets of existing power, and we bring it online in months, not years.”

Michael Maniscalco, CEO of QumulusAI
4:07 PM ET 8-K
Financial Results Fold Holdings, Inc. FLD

Fold Holdings Financial Results

Fold Holdings reported Q3 2026 financial results, highlighting a 270% increase in custody and trading revenue and the launch of Fold Reserve and Lead Bank accounts. The company reduced operating expenses by 21% year-over-year and is transitioning its business model from transaction-based to balance-based economics.

Term
Q3 2026

“We believe Q3 was an inflection point for Fold. Over the last few months we’ve evolved from strictly a transaction-based business to one that also monetizes customer balances, broadened our focus from bitcoin earners to every American who earns rewards, strengthened our balance sheet, maintained a focus on operational efficiency, and opened new distribution channels that take our products to audiences we’ve never reached before.”

Will Reeves, Chairman and CEO

“We are reshaping Fold from a business built on gathering customers into one built on gathering assets. A transaction pays us once. A customer balance earns for us every month it stays on the platform, and it ties that customer more closely to everything else we offer.”

Will Reeves, Chairman and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.